Despite a tremendous advances in the therapeutic options for melanoma patients (Figure 1), inability or limited vulnerability of melanoma cells to induction of apoptosis in response to inhibitors of BRAFmut (BRAFi) and MEK (MEKi) [31,32,33,34,35,36,37,38], and escape from immunotherapy [39,40,41] are the reasons for re-growth of drug-resistant disease. Here, MAP2K7 is linked to melanoma.